Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA

Full IRB Study Title:
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase

IRB Study ID: 160901

For complete information, please visit the study on clinicaltrials.gov

Study Sponsor:

Sanofi / Regeneron Pharmaceuticals

Akron Children‘s Anywhere Mobile App

Managing your child‘s health, made easier

Akron Children‘s Anywhere Mobile App

Managing your child‘s health, made easier

Akron Children‘s Anywhere is designed to be your “go-to app” for managing your child‘s health. It provides tools for finding a primary care doctor or specialist, finding locations and directions, and making everyday health decisions as well as giving you quick, secure access to MyChart and other tools. And when your child needs care, the renowned experts at Akron Children‘s are just one tap away.

Apple App Store Anywhere Mobile App Download Button

Google Play Anywhere Mobile App Download Button

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.